

## Psychokardiologie des alten Patienten: die Aortenstenose als Modellerkrankung

*M. Franz, L. Bäß, G. Dannberg*

1. Mojtabai R, Jorm AF. Trends in psychological distress, depressive episodes and mental health treatment-seeking in the United States: 2001–2012. *J Affect Disord* 2015; 174: 556–61
2. Lichtman JH et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. *Circulation* 2014; 129(12): 1350–69
3. Thombs BD et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. *JAMA* 2008; 300 (18): 2161–71
4. Somberg TC, Arora RR. Depression and heart disease: therapeutic implications. *Cardiology* 2008; 111(2): 75–81
5. Williams JB et al. Preoperative anxiety as a predictor of mortality and major morbidity in patients aged > 70 years undergoing cardiac surgery. *Am J Cardiol* 2013; 111(1): 137–42
6. Huffman JC et al. Depression and cardiac disease: epidemiology, mechanisms, and diagnosis. *Cardiovasc Psychiatry Neurol* 2013; 695925
7. Erzen E, Cikrikci O. The effect of loneliness on depression: A meta-analysis. *Int J Soc Psychiatry* 2018; 64(5): 427–35
8. Celano CM et al. Depression and Anxiety in Heart Failure: A Review. *Harv Rev Psychiatry* 2018; 26(4): 175–84
9. Go AS et al. American Heart Association Statistics C, Stroke Statistics S Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. *Circulation* 2014; 129(3): e28–e292
10. Messika-Zeitoun D et al. Aortic valve calcification: determinants and progression in the population. *Arterioscler Thromb Vasc Biol* 2007; 27(3): 642–48
11. Gaede L et al. Transcatheter-based aortic valve replacement vs. isolated surgical aortic valve replacement in 2020. *Clin Res Cardiol* 2022; 111(8): 924–33
12. Spaccarotella C et al. Pathophysiology of aortic stenosis and approach to treatment with percutaneous valve implantation. *Circ J* 2011; 75(1): 11–19
13. Prendergast BD, Redwood SR, Patterson T. TAVR Versus SAVR in Aortic Stenosis: Long Journey, New Roadmap. *J Am Coll Cardiol* 2021; 77(9): 1162–64
14. Vahanian A et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur J Cardiothorac Surg* 2021; 60(4): 727–800
15. Gu S et al. Does Transcatheter Aortic Valve Implantation for Aortic Stenosis Impact on Cognitive Function? *Cardiol Rev* 2020; 28(3): 135–39
16. Khan MM et al. Cognitive Outcomes After Transcatheter Aortic Valve Implantation: A Metaanalysis. *J Am Geriatr Soc* 2018; 66(2): 254–62
17. Lai KS et al. Cognitive Outcomes following Transcatheter Aortic Valve Implantation: A Systematic Review. *Cardiovasc Psychiatry Neurol* 2015; 209569

18. Khan MM et al. The value of screening for cognition, depression, and frailty in patients referred for TAVI. *Clin Interv Aging* 2019; 14: 841–48
19. Lange R et al. Quality of Life After Transcatheter Aortic Valve Replacement: Prospective Data From GARY (German Aortic Valve Registry). *JACC Cardiovasc Interv* 2016; 9(24): 2541–54
20. Hoyl MT et al. Development and testing of a five-item version of the Geriatric Depression Scale. *J Am Geriatr Soc* 1999; 47(7): 873–78
21. Drudi LM et al. Association of Depression With Mortality in Older Adults Undergoing Transcatheter or Surgical Aortic Valve Replacement. *JAMA Cardiol* 2018; 3(3): 191–97
22. Baz L et al. Depression and anxiety in elderly patients with severe symptomatic aortic stenosis persistently improves after transcatheter aortic valve replacement (TAVR). *Int J Cardiol* 2020; 309: 48–54
23. Baz L et al. Delayed Improvement of Depression and Anxiety after Transcatheter Aortic Valve Implantation (TAVI) in Stages of Extended Extra-Valvular Cardiac Damage. *J Clin Med* 2021; 10(8)
24. Tamm AR et al. Quality of life in patients with transcatheter aortic valve implantation: an analysis from the INTERVENT project. *Front Cardiovasc Med* 2023; 10: 1181771
25. Eide LSP et al. Anxiety and depression in patients aged 80 years and older following aortic valve therapy. A six-month follow-up study. *Aging Clin Exp Res* 2023; 35(11): 2463–70
26. Genereux P et al. Staging classification of aortic stenosis based on the extent of cardiac damage. *Eur Heart J* 2017; 38(45): 3351–58
27. Varghese TP et al. Interplay of inflammatory biomarkers in heart disease patients with depressive symptoms: An update. *Curr Probl Cardiol* 2024; 49(3): 102352
28. Dalberto M et al. Frailty, depression and prognosis after transcatheter aortic valve replacement: a literature review. *Geriatr Psychol Neuropsychiatr Vieil* 2021
29. Bäßler LC et al. Preexisting depression independently predicts 3-year mortality after transcatheter aortic valve implantation (TAVI). 90. Jahrestagung der Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (German Cardiac Society). *Clinical Research in Cardiology* 2024
30. El-Sabawi B et al. Association of Depression and Cognitive Dysfunction With Patient-Centered Outcomes After Transcatheter Aortic Valve Replacement. *Circ Cardiovasc Interv* 2023; 16(8): e012875
31. Wegermann ZK et al. Anxiety and Depression Following Aortic Valve Replacement. *J Am Heart Assoc* 2022; 11(9): e024377
32. Sun J et al. Comparison of the levels of depression and anxiety in elderly aortic stenosis patients treated with surgical or transcatheter aortic valve replacement. *J Cardiothorac Surg* 2022; 17(1): 141
33. Horn N et al. Baseline depressive symptoms, personal control, and concern moderate the effects of preoperative psychological interventions: the randomized controlled PSY-HEART trial. *J Behav Med* 2022; 45(3): 350–65
34. Salzmann S et al. Pre-surgery optimization of patients' expectations to improve outcome in heart surgery: Study protocol of the randomized controlled multi-center PSY-HEART-II trial. *Am Heart J* 2022; 254: 1–11
35. Horn N et al. Preoperative optimization of cardiac valve patients' expectations: Study protocol of the randomized controlled ValvEx-trial. *Front Cardiovasc Med* 2023; 10: 1105507

36. Brand A et al. Medical Graphic Narratives to Improve Patient Comprehension and Periprocedural Anxiety Before Coronary Angiography and Percutaneous Coronary Intervention: A Randomized Trial. *Ann Intern Med* 2019; 170(8): 579–81
  37. Brand A et al. Medical graphics to improve patient understanding and anxiety in elderly and cognitively impaired patients scheduled for transcatheter aortic valve implantation (TAVI). *Clin Res Cardiol* 2023
  38. Bäßler L TF et al. Evaluation of a medical education comic in anxious patients before transcatheter aortic valve implantation: patient satisfaction and effects on individual disease experience. 90. Jahrestagung der Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (German Cardiac Society). *Clin Res Cardiol* 2024
- 

## **Psychokardiologische Aspekte in der ambulanten Versorgung von Patienten mit Herz-Kreislaufkrankungen**

### *B. Leithäuser*

1. Albus C et al. Bedeutung von psychosozialen Faktoren in der Kardiologie – Update 2018. *Kardiologie* 2018; 12: 312–31
2. Mindham R et al. How your patient is really feeling: the emotional hinterland of a cardiac diagnosis. *Eur Heart J*. 2024; 45: 748–50
3. Ladwig KH, Lukaschek K. Psychosoziale Risikofaktoren in einer personalisierten kardiologischen Prävention. *PiD - Psychotherapie im Dialog* 2021; 22: 19–24
4. Levine GN et al. Psychological Health, Well-Being, and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart Association. *Circulation* 2021; 143: e763–e83
5. Borgi M et al. Cardiovascular disease and mental health: a dangerous duo? *Eur J Prev Cardiol* 2023; 30: 1686–88
6. Lichtman JH et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. *Circulation* 2008; 118: 1768–75
7. Jha MK et al. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2019; 73: 1827–45
8. Selye H. The evolution of the stress concept. *Am Sci* 1973; 61: 692–99
9. Sara JDS et al. Mental Stress and Its Effects on Vascular Health. *Mayo Clin Proc* 2022; 97: 951–90
10. Madsen IEH et al. Job strain as a risk factor for clinical depression: systematic review and meta-analysis with additional individual participant data. *Psychol Med* 2017; 47: 1342–56
11. Waller C. Stress und Psychobiologie bei kardiovaskulären Erkrankungen. *PiD - Psychotherapie im Dialog* 2021; 22: 32–37
12. Eller NH et al. Work-related psychosocial factors and the development of ischemic heart disease: a systematic review. *Cardiol Rev* 2009; 17: 83–97

13. Skoda EM et al. Veränderung der psychischen Belastung in der COVID-19-Pandemie in Deutschland: Ängste, individuelles Verhalten und die Relevanz von Information sowie Vertrauen in Behörden. Bundesgesundheitsbl 2021, 64: 322–33
14. Shibata S et al. COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. Hypertens Res 2023; 46: 589–600
15. Dong M & Zheng J. Letter to the editor: Headline stress disorder caused by Netnews during the outbreak of COVID-19. Health Expect 2020; 23: 259–60
16. Wang S et al. Association of social isolation and loneliness with the risk of hypertension in middle aged and older adults: Findings from a national representative longitudinal survey. J Affect Disord 2024; 349: 577–82
17. Williams B et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021–104
18. Rüdell H. Ist die arterielle Hypertonie eine psychosomatische Erkrankung? PiD - Psychotherapie im Dialog 2011; 12: 61–65
19. Schaare HL et al. Associations between mental health, blood pressure and the development of hypertension. Nat Commun 2023; 14: 1953
20. Herrmann-Lingen C & al'Absi M. Exploring the Association of Hypertension With Risk for Depression: Evidence for Tamed Neurobehavioral Arousal Versus Central Emotional Dysregulation. Psychosom Med 2018; 80: 504–7
21. Wang L et al. Effects of Combination Treatment in Hypertensive Patients with Depression: A Systematic Review and Meta-Analysis of 27 Randomized Controlled Trials. Ther Clin Risk Manag 2022; 18: 197–211
22. Li Y et al. The efficacy of cognitive behavioral therapy-based interventions on patients with hypertension: A systematic review and meta-analysis. Prev Med Rep 2021; 23: 101477
23. Kariis HM et al. The role of depression and antidepressant treatment in antihypertensive medication adherence and persistence: Utilising electronic health record data. J Psychiatr Res 2023; 168: 269–78
24. Kessing LV et al. Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study. Hypertension 2020; 76: 1263–79
25. Herrmann-Lingen C Albus C, Titscher G (Hrsg). Psychokardiologie. Ein Praxisleitfaden für Ärzte und Psychologen. 2020; Springer Berlin, Heidelberg
26. Leithäuser B. SOP-Abklärung psychischer Komorbidität bei kardialen Erkrankungen in der Praxis. Kardiologie up2date 2023; 19: 13–17

---

## **Biofaktoren in der Psychokardiologie: Bei stressbedingten Herzerkrankungen Magnesiummangel vermeiden**

*D. Birkelbach, K. Kisters, H.-G. Classen*

1. Pickering G et al. Magnesium Status and Stress: The Vicious Circle Concept Revisited. Nutrients 2020; 12(12): 3672
2. Selye H. Stress and the general adaptation syndrome. Br Med J 1950; 1: 1383–92

3. Ullmann E et al. From Allostatic Load to Allostatic State – An Endogenous Sympathetic Strategy to Deal With Chronic Anxiety and Stress? *Front Behav Neurosci* 2019; 13: 47
4. Clark MS et al. Environmental stress, psychological stress and allostatic load. *Psychol Health Med* 2007; 12(1): 18–30
5. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. *Eur J Pharm* 2003; 463(1–3): 235–72
6. Lanfumey L et al. Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. *Neurosci Biobehav Rev* 2008; 32(6): 1174–84
7. Yulug B et al. Brain-derived neurotrophic factor, stress and depression: A minireview. *Brain Res Bull* 2009; 78(6): 267–69
8. Brosschot JF et al. The default response to uncertainty and the importance of perceived safety in anxiety and stress: An evolution-theoretical perspective. *J Anxiety Disord* 2016; 41: 22–34
9. McEwen BS, Akil H. Revisiting the Stress Concept: Implications for effective Disorders. *J Neurosci* 2020; 40(1): 12–21
10. Chrousos GP. Stress and disorders of the stress system. *Nat Rev Endocrinol* 2009; 5(7): 374–81
11. Anger P et al. Stress: psychosocial work load and risks for cardiovascular disease and depression. *Dtsch med Wochenschr* 2014; 139(24): 1315–19
12. Galland L. Magnesium, stress and neuropsychiatric disorders. *Magnes Trace Elem* 1991-1992; 10(2–4): 287–301
13. Classen HG. Systemic stress, magnesium status and cardiovascular damage. *Magnesium* 1986, 5: 105–10
14. Murck H. Magnesium and effective disorders. *Nutr Neurosci* 2002; 5(6): 375–89
15. Cuciureanu M, Vink R. Magnesium and stress. In *Magnesium in the Central Nervous System*; Vink, R., Nechifor, M., Eds.; University of Adelaide Press: Adelaide, Australia, 2011
16. Pochwat B et al. Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway. *Psychopharmacol* 2015; 232(2): 355–67
17. Zheltova AA et al. Magnesium deficiency and oxidative stress: An update. *Biomedicine (Taipei)* 2016; 6(4): 20
18. Zogović D et al. Pituitary-gonadal, pituitary-adrenocortical hormonal and IL-6 levels following long-term magnesium supplementation in male students. *J Med Biochem* 2014; 33: 291–98
19. Nielsen FH et al. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep. *Magnes Res* 2010; 23(4): 158–68
20. Wienecke E et al. Langzeit-HRV-Analyse zeigt Stressreduktion durch Magnesiumzufuhr. *MMW* 2016; 158(S6): 12–16
21. Nielsen FH. Dietary Magnesium and Chronic Disease. *Adv Chronic Kidney Dis* 2018; 25(3): 230–35
22. Kisters K et al. Ionized magnesium deficiency in elderly hypertensive patients in a pilot study. *Nutr Food Sci J* 2020; 3(2): 129–34
23. Micke O et al. Magnesium – Bedeutung für die hausärztliche Praxis: Positionspapier der Gesellschaft für Magnesium-Forschung e.V. *Dtsch Med Wochenschr* 2020; 145(22): 1628–34
24. Wannamethee SG et al. Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study. *Eur J Epidemiol* 2018; 33(9): 873–82

25. Song Y et al. Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. *Am J Cardiol* 2006; 98: 1616–21
26. Ascherio A et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. *Hypertension* 1996; 27: 1065–72
27. Verma H et al. Effect of magnesium supplementation on type 2 diabetes associated cardiovascular risk factors: A systematic review and meta-analysis. *J Hum Nutr Diet* 2017; 30: 621–33
28. Kass LS et al. Effect of magnesium supplementation on blood pressure: A meta-analysis. *Eur J Clin Nutr* 2012; 66: 411–18
29. Zhang X et al. Effects of magnesium supplementation on blood pressure. A meta-analysis of randomized double-blind placebo-controlled trials. *Hypertension* 2016; 68(2): 324–33
30. Kisters K, Classen HG et al. Magnesiumhaushalt und Therapie bei Hypertonie. *Nieren- und Hochdruckkrankheiten* 2020; 245–51
31. Kisters K. Oral magnesium supplementation improves borderline hypertension. *Magnes Res* 2011; 24: 17–18
32. Kisters K et al. Low ionized magnesium, vitamin d and interleukin 6 concentration in elderly hypertensive patients. *Trace Elem and Elektrolytes* 2021; 38(2): 63–7
33. Kisters K et al. Positive Effect of Magnesium Orotate Therapy in Hypertensive Heart Disease. *Metabolomics* 2017; 7: 3–7
34. Tangvoraphonkchai K et al. Magnesium and Cardiovascular Disease. *Adv Chronic Kidney Dis* 2018; 25(3): 251–60
35. Stepura OB et al. Magnesiumorotat in severe congestive heart failure (MACH). *Int J Cardiol* 2009; 131: 292–95
36. Kisters K et al. Positiver Effekt einer Magnesiumorotat-Therapie bei hypertensiver Herzerkrankung. *Nieren- u. Hochdruckkrankheiten* 2016; 45: 1–6
37. Viskin S. Torsads de Pointes. *Curr Treat Options Cardiovasc Med* 1999; 1(2): 187–95
38. Kieboom BCT et al. Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death. *J Am Heart Assoc* 2016; 5(1): e002707
39. Rosanoff A et al. Recommendation on an updated standardization of serum magnesium reference ranges. *Eur J Nutr* 2022; 61(7): 3697–706
40. Micke et al. Serum magnesium: time for a standardized and evidence-based reference range. *Magnes Res* 2021; 34(2): 84–9
41. Durlach J. *Magnesium in Clinical Practice*. J. Libbey, London 1988: 229
42. Classen HG et al. Magnesiummangel bei Normomagnesiämie: Elektrolyte, Vitamine, Spurenelemente – Kriterien eines erhöhten Bedarfs in Zielorganen bei normalen Plasmawerten. Hrsg.: Biesalski HK, Classen HG; Georg Thieme Verlag 1995: 38–43
43. Rylander R. Bioavailability of magnesium salts – A review. *J Pharm Nutr Sci* 2014; 4: 57–9
44. Blancquaert L et al. Predicting and Testing Bioavailability of Magnesium Supplements. *Nutrients* 2019; 11(7): 1663